ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gilead Sciences, Renown Institute for Health Innovation collaborate for NASH
July 16, 2019Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000
Pharma Sources Insight January 2025
